This review outlines future treatment strategies and future prospects for ALK-p, ALK inhibitor-naïve advanced NSCLC with CNS metastasis, with a focus on elucidating and overcoming acquired resistance mechanisms. This evidence concerns the gene ALK and non-small cell lung carcinoma.